The Rise and Fall of PLOS ONE's Impact Factor (2012 = 3.730)
Are we witnessing the decline of the open access megajournal and a return to a discipline-based model of publishing?
Are we witnessing the decline of the open access megajournal and a return to a discipline-based model of publishing?
Here is how CHORUS works, in its simplest form.
Like rock and roll, Open Access is here to stay but, as with rock and roll, it doesn’t always live up to its own hype.
As Day 1 of the SSP Annual Meeting draws to a close, a few ideas seemed worth sharing.
In this special SSP Annual Meeting edition of the Scholarly Kitchen podcast, Stewart Wills sits down with Tim O’Reilly of O’Reilly Media — and keynote speaker — to discuss favorite books, creating value, and the importance of diversifying your business.
A proposed partnership between publishers and the US government in response to the OSTP memorandum may show the way forward for public-private networked information solutions.
An interview with Susan King of the CHORUS steering group about the publisher response to the OSTP public access memorandum.
Authors should not be surprised when their open access articles show up in surprising places. Is it possible to embrace open access with some restrictions?
More internal PubMed Central emails show quite clearly that PMC is wasting taxpayers’ money solving problems publishers have already solved.
Eighteen years ago, Mosaic ushered in the potential for a sea-change in publishing based on technological prowess and scale. Today, the “open” label covers a set of disparate incentives under a single blanket, one that funders, government, and technology companies are all under, each for its own reason.
The OSTP access memorandum has led to hearings this month. Be sure to contribute and observe.
While the access debates have dominated, another debate has been emerging, one that perhaps has greater significance in the long run.
A summary with slides of a presentation for the Council of Scientific Society Presidents (CSSP). The argument is that professional societies are now fighting on three fronts: with the new open access mandates, with the large commercial competitors, and sometimes internally when governance is an issue.
Articles are published before they’re reviewed; doubts about a paper are viewed as a positive status; papers only need to contain “science;” review and revision can continue forever; and PubMed Central is their certifying entity. Welcome to the world of F1000 Research.
The recent sale of Mendeley exposed surprisingly naive perspectives on the company’s clear and inherent goals. Other venture capital plays are afoot in scientific publishing and academia. When will we stop being the prey?